KNTE insider transaction filings

Kinnate Biopharma Inc. — 17 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-04-05. Screen KNTE transaction legs live →

Insider transaction summary — last 90 days

No Form 4 filings for KNTE between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.

Recent Form 4 filings — Kinnate Biopharma Inc.

FiledFormInsiderReported transactionsSource
2024-04-054Farzan Nima — CHIEF EXECUTIVE OFFICER, DirectorDisposition to issuer (D): 2,186 · Disposition to issuer (D): 1,281,642 (derivative) · Disposition to issuer (D): 437,413 (derivative) · Disposition to issuer (D): 275,000 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 750,000 (derivative)EDGAR
2024-04-054Krishnamohan Neha — CHIEF FINANCIAL OFFICERDisposition to issuer (D): 64,087 · Disposition to issuer (D): 270,000 (derivative) · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 215,000 (derivative)EDGAR
2024-04-054Epperly Melissa B, — DirectorDisposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054Rome Michael E — DirectorDisposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054DeSimone Jill — DirectorDisposition to issuer (D): 50,000 (derivative)EDGAR
2024-04-054Meltz Mark A — COO GENERAL COUNSEL SECRETARYDisposition to issuer (D): 27,578 · Disposition to issuer (D): 384,508 (derivative) · Disposition to issuer (D): 121,503 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 135,000 (derivative) · Disposition to issuer (D): 215,000 (derivative)EDGAR
2024-04-054Sabzevari Helen — DirectorDisposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054Foresite Capital Management IV, LLC — 10% owner
Foresite Capital Fund IV, L.P. — 10% owner
Foresite Capital Management V, LLC — 10% owner
Foresite Capital Fund V, L.P. — 10% owner
Foresite Capital Opportunity Management V, LLC — 10% owner
Foresite Capital Opportunity Fund V, L.P. — 10% owner
Disposition to issuer (D): 9,671,643 · Disposition to issuer (D): 3,525,957 · Disposition to issuer (D): 520,711EDGAR
2024-04-054Tananbaum James B. — Director, 10% ownerDisposition to issuer (D): 9,671,643 · Disposition to issuer (D): 3,525,957 · Disposition to issuer (D): 520,711 · Disposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 20,250 (derivative)EDGAR
2024-04-054Smaldone Alsup Laurie — DirectorDisposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative)EDGAR
2024-04-054Flaherty Keith T. — DirectorDisposition to issuer (D): 66,377 · Disposition to issuer (D): 32,064 (derivative) · Disposition to issuer (D): 56,112 (derivative) · Disposition to issuer (D): 11,391 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · +1 moreEDGAR
2024-04-054GORDON CARL L — Director, 10% ownerDisposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 · Disposition to issuer (D): 40,501 (derivative) · +2 moreEDGAR
2024-04-054MITCHELL DEAN J — DirectorDisposition to issuer (D): 121,503 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative)EDGAR
2024-04-054ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Capital GP VIII LLC — Director, 10% owner
OrbiMed Asia GP IV, L.P. — Director, 10% owner
OrbiMed Advisors IV Ltd — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
ORBIMED CAPITAL LLC — Director, 10% owner
Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000EDGAR
2024-03-054Krishnamohan Neha — CHIEF FINANCIAL OFFICERTax withholding (F): 1,506 @ $2.59EDGAR
2024-03-054Williams Richard Thomas — CHIEF MEDICAL OFFICERTax withholding (F): 558 @ $2.59EDGAR
2024-03-054Meltz Mark A — COO GENERAL COUNSEL SECRETARYTax withholding (F): 558 @ $2.59EDGAR

Recent 8-K events — Kinnate Biopharma Inc.

FiledFormItems reportedSource
2024-04-038-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-018-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-168-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-01-168-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=KNTE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →